NCT05640102 2026-03-04
Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia
BeOne Medicines
Recruiting
Clinical Trials
9 trialsNCT04116437 2026-01-28
Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment
BeOne Medicines
Phase 2 Completed
NCT05952037 2026-01-02
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
BeOne Medicines
Phase 2 Active not recruiting
NCT07169331 2025-12-19
A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia
BeOne Medicines
Phase 4 Recruiting
NCT04172246 2025-11-21
Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies
BeOne Medicines
Phase 1/2 Completed
NCT05326308 2025-09-23
ARIADNE
iOMEDICO AG
Recruiting
NCT03053440 2024-10-26
ASPEN
BeiGene
Phase 3 Completed
NCT03332173 2024-10-26
Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)
BeiGene
Phase 2 Completed
NCT04052854 2024-10-23
A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies
BeiGene
No longer available